Loading…
← CockpitCompetitor Analysis › 6855.HK Ascentage Pharma Group InternationalOpen in the cockpit ↗

Ascentage Pharma Group International6855.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major

Chinese biotech developing apoptosis-targeting cancer drugs, including approved CML drug olverembatinib and Bcl-2 inhibitor lisaftoclax.

≈ A Chinese AbbVie-style apoptosis/oncology drug developerMomentum weak 21
Mkt cap
$1.18B
US dollars, full cap
Free float
81%
of shares outstanding
$/day
$8.80M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-155.6 pp
WACC 8.4%
Hurdle
n/a
no reverse DCF
Next earnings
133 days
31 Mar 2027
Close · HKDHK$24.82
1D-3.1%
1W-14.8%
1M-18.8%
3M-28.6%
6M-34.2%
YTD-52.5%
1Y-60.3%
ATR %6.6%
52w lowhigh64.1% off high

What Ascentage Pharma Group International does

Chinese biotech developing apoptosis-targeting cancer drugs, including approved CML drug olverembatinib and Bcl-2 inhibitor lisaftoclax.

Sells olverembatinib itself in China, and funds the rest of its pipeline partly from licence fees and milestone payments from larger pharma partners, with a loss-making profile typical of a company paying for late-stage trials. Hospitals in China are the buyers, with insurance reimbursement important for volumes.

In one line: A Chinese AbbVie-style apoptosis/oncology drug developer.

Products and services

  • Olverembatinib (CML)
  • Lisaftoclax (Bcl-2 inhibitor)
  • Oncology pipeline

Customers

  • Hospitals/oncologists in China
  • Global licensing partners

Where it sits in the supply chain

  • Biotechnology
  • Small-molecule oncology drugs
  • Apoptosis-targeted therapeutics

What could go right

  • Global licensing/partnership deals
  • New indication approvals

What could go wrong

  • Clinical trial risk
  • Cash burn pre full profitability

Moat: narrow (IP / patents, first-mover approval). Approved BCR-ABL inhibitor for drug-resistant CML with patent protection.

Headquarters: Suzhou, China · Founded: 2009 · Employees: 767

Named competitors

Ascentage Pharma Group International at a glance

Size Ascentage Pharma Group International (6855.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $1.18B, the 540th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$24.82 on 18 Nov 2026.

Performance Over six months the shares fell 34.2%, against -11.8% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 7th lowest of 20 in its peer set.

Growth Revenue grew 70.3% over the last twelve months (peer median +5.9%); the operating margin is -220.0% (peer median 0.8%).

Valuation It trades at 13.2× enterprise value to sales against a peer median of 7.6× (5th most expensive of 18).

Capital Return on invested capital runs 155.6 points below its cost of capital (8.4% WACC).

Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 866855.HK 64
Six months, rebased to 100: Ascentage Pharma Group International against the median of its 20 peers (local-currency closes).

Ascentage Pharma Group International financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$717MHK$623MHK$1.06BHK$245MHK$244M
Revenue growth—-41%+333%+1%—
Gross profitHK$597MHK$493MHK$940MHK$126MHK$147M
EBITDA-HK$1.48B-HK$1.22B-HK$310M-HK$900M-HK$956M
Net income-HK$1.64B-HK$1.35B-HK$440M-HK$1.02B-HK$1.03B
Free cash flow-HK$1.58B-HK$1.38B-HK$213M-HK$947M-HK$1.08B
Capital expenditureHK$22.2MHK$29.9MHK$26.3MHK$62.8MHK$276M
Total debtn/aHK$2.21BHK$1.81BHK$1.98BHK$2.01B

Quarterly statements and history in the cockpit →

Ascentage Pharma Group International competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%NKTR6884436883210009896880623000062616HROW4547347850002550IDIA300026CMHCAVLNGPCRVIYASH2376906855.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Ascentage Pharma Group International is the large dot.

Fundamentals: revenue growth against valuation

-100%0%+100%+200%0×250×500×750×NKTR6884436883210009893000062616347850CMHCVIYASH6855.HKRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Ascentage Pharma Group International is the large dot.

Ascentage Pharma Group International competitors and peer comparison

Head to head with its named competitors (6855.HK vs ABBV vs 9969.HK)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Ascentage Pharma Group International 6855.HK$1.18B-34%+70%-220%13.2×n/a
AbbVie ABBV$506B+35%+11%36%8.7×-0.1%
InnoCare Pharma 9969.HK$2.01B-10%+146%35%2.8×-2.0%

How Ascentage Pharma Group International compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Ascentage Pharma Group International against its 20 peers (data as of 18 Nov 2026)
Measure6855.HKPeer medianRank in peer set
1-month return-18.8%-1.6%4th lowest of 21
6-month return-34.2%-11.8%7th lowest of 20
Distance from 52-week high-64.1%-39.3%4th lowest of 21
Revenue growth (TTM)+70.3%+5.9%4th highest of 18
Operating margin-220.0%0.8%3rd lowest of 18
EV / Sales13.2×7.6×5th most expensive of 18
ROIC minus cost of capital-155.6 pp-7.5 pplowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Ascentage Pharma Group International 6855.HKHong Kong$1.18B-34%+70%-220%13.2×n/an/a
Nektar Therapeutics NKTRUnited States$1.18B-50%-17%-304%13.3×n/an/a
Chongqing Genrix Biopharmaceutical 688443.SSChina$1.18B-22%+256%-27%8.6×n/an/a
Shenzhen Chipscreen Biosciences 688321.SSChina$1.18B-38%+27%12%7.6×n/an/a
Jiuzhitang 000989.SZChina$1.16B-7%+46%19%2.6×-4.0%-9.0%
Mabwell (Shanghai) Bioscience 688062.SSChina$1.20B-46%+15%-129%13.3×n/an/a
Chongqing Lummy Pharmaceutical 300006.SZChina$1.21B+26%-6%-19%10.4×44.1%-13.2%
CStone Pharmaceuticals 2616.HKHong Kong$1.21B-22%+117%-89%17.0×n/an/a
Harrow HROWUnited States$1.21B+4%+21%1%4.7×n/an/a
Kissei Pharmaceutical 4547.TJapan$1.14B+3%+6%6%1.4×n/an/a
D&D Pharmatech 347850.KSSouth Korea$1.22B-49%-77%-2,324%818.8×n/an/a
Changzhou Qianhong Bio-Pharma 002550.SZChina$1.14B-12%-2%15%4.2×3.4%-1.2%
Idorsia IDIA.SWSwitzerland$1.22B-9%-5%-70%10.4×n/an/a
Tianjin Chase Sun Pharmaceutical 300026.SZChina$1.23B-10%-29%3%1.8×7.0%-5.3%
Cosmo CMHC.SWSwitzerland$1.13B-30%-45%-13%8.2×n/an/a
Avalyn Pharma AVLNUnited States$1.23B-1%n/an/an/an/an/a
GC Biopharma 006280.KSSouth Korea$1.12B-10%-3%4%1.2×n/an/a
Structure Therapeutics, Inc. Sponsored ADR GPCRUnited States$1.24B-53%n/an/an/an/an/a
Symbiotec Pharmalab SYMBIOTEC.NSIndia$1.12Bn/an/an/an/an/an/a
Viyash Scientific VIYASH.NSIndia$1.11B+3%+124%13%2.9×36.3%+20.4%
ST Pharm 237690.KSSouth Korea$1.11B-51%+26%18%3.5×4.2%+21.7%

Questions

Who are Ascentage Pharma Group International's main competitors?
Named competitors: AbbVie (ABBV), BeiGene (private or unlisted), InnoCare Pharma (9969.HK). The cockpit's measured peer set (industry) also includes Nektar Therapeutics (NKTR), Chongqing Genrix Biopharmaceutical (688443.SS), Shenzhen Chipscreen Biosciences (688321.SS), Jiuzhitang (000989.SZ), Mabwell (Shanghai) Bioscience (688062.SS), Chongqing Lummy Pharmaceutical (300006.SZ).
Is Ascentage Pharma Group International expensive compared with its peers?
On ev / sales it trades at 13.2× against a peer median of 7.6×, 5th most expensive of 18 in its peer set.
How has Ascentage Pharma Group International stock performed?
Over six months to 18 Nov 2026 the shares returned -34.2% against -11.8% for the median peer; over one year -60.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.